Trevi Therapeutics, Inc. (TRVI) analyst actions
Rating and price-target actions on TRVI in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the TRVI overview →
2 measured TRVI analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF) | Press release | -1.75% | -6.14% | |
| Trevi Therapeutics Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio™ for Refractory Chronic Cough | Press release | +0.00% | -8.79% |
Keep exploring
More TRVI: earnings → · SEC filings → · TRVI overview →